Haddad Bassam, Lecarpentier Edouard, Touboul Cyril, Sibai Baha M
*Department of Obstetrics, Gynecology, and Reproductive Medicine, University Paris Est Créteil, CRC Centre Hospitalier Intercommunal de Créteil, Créteil, France †Department of Obstetrics and Gynecology, Maternal-Fetal Medicine Division, McGovern Medical School at UT Health, Houston, Texas.
Clin Obstet Gynecol. 2017 Mar;60(1):153-160. doi: 10.1097/GRF.0000000000000252.
During the past decade, prophylactic doses of low-molecular-weight heparin (LMWH) have been suggested to decrease the risk of placental-mediated complications. Herein, we review the prospective randomized trials that addressed the usefulness of LMWH in preventing placental-mediated complications in high-risk women. Inclusion criteria and results of these trials are heterogeneous. Unlike older trials (3 of 4 are single center), recent trials (all are multicenter) do not show beneficial effect of LMWH. There is certainly a need of complementary research before stating on the usefulness of LMWH in the prevention of placenta-mediated pregnancy complications in women at high risk.
在过去十年中，有人提出预防性剂量的低分子量肝素（LMWH）可降低胎盘介导并发症的风险。在此，我们回顾了针对LMWH在预防高危女性胎盘介导并发症方面的有效性的前瞻性随机试验。这些试验的纳入标准和结果各不相同。与早期试验（4项中有3项为单中心试验）不同，近期试验（均为多中心试验）未显示LMWH有有益效果。在阐述LMWH在预防高危女性胎盘介导的妊娠并发症方面的有效性之前，确实需要进行补充研究。
